Emmaus Enters License and Exclusive Distribution Agreement with NeoImmuneTech

Emmaus Life Sciences Inc., a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, has granted NeoImmuneTech Inc. (NIT) an exclusive license to all rights to market, sell and distribute Endari (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a royalty on NIT’s product sales.

The deal is subject to NIT’s obtaining the necessary regulatory approvals and licensing to sell and distribute the products and other specified conditions.

“Emmaus has continuously reassessed its commercialization strategy to maximize global value of Endari. While the U.S. market represents a mature and stable revenue base, we believe other regions such as the Middle East, Brazil, and Europe offer greater growth potential,” commented Willis Lee, Chairman and CEO of Emmaus.

Tae Woo Kim, Acting CEO of NeoImmuneTech, said, “The completion of this definitive agreement is highly meaningful, as it establishes a foundation for direct commercialization of an FDA-approved therapy. The U.S. distribution, reimbursement, and marketing infrastructure built through Endari will also create significant synergies for the future commercialization of our proprietary pipeline, including NT-I7.”